Isolation and Characterization of the Lytic Bacteriophages and Its Application in Combination with Amoxicillin against Aeromonas dhakensis

Aeromonas dhakensis is the most virulent Aeromonas species in tropical and subtropical areas and causes a variety of human diseases. Owing to its resistance against some antibiotics, there is an urgent need for new strategies against this pathogen. This is the first study to isolate and characterize lytic phages against A. dhakensis. Of Aeromonas isolates, only isolate AM could be used to isolate phages using the enrichment technique. This strain was identified via biochemical tests, 16S rDNA sequencing, and whole-genome analyses. All results confirmed that strain AM was A. dhakensis. In silico detection of antimicrobial resistance genes and virulence factors corresponding to the main bacterial virulence determinants were observed in A. dhakensis AM, which was then used as the host for phage isolation. Four lytic phages, designated vB_AdhS_TS3, vB_AdhM_TS9, vB_AdhM_DL, and vB_AdhS_M4, were isolated. Transmission electron micrographs showed that vB_AdhS_TS3 and vB_AdhS_M4 belonged to Siphoviridae family, whereas vB_AdhM_TS9 and vB_AdhM_DL belonged to Myoviridae family. Host-range determination demonstrated that all phages were capable of infecting only A. dhakensis. Three phages, vB_AdhS_TS3, vB_AdhM_TS9, and vB_AdhM_DL, were selected since they had a shorter latency period and larger burst sizes. All phages were resistant to a wide range of pH values and remained relatively stable after a 60-minute incubation at 4 °C, 25 °C, 30 °C, and 37 °C but were sensitive to higher temperatures. The pre-treatment (co-inoculation of A. dhakensis and phage) with individual phages and phage cocktails reduced bacterial numbers in the range of 2.82-6.67 and 5.19-5.43 log CFU/mL, respectively, after 6 h of incubation. In post-treatment, the maximum inactivation was achieved with the log reduction of bacterial number in the range of 3.06-5.25 and 4.01-6.49 log CFU/mL after 6 and 12 h of incubation, respectively. A combination of phage cocktail with amoxicillin at sub-MIC showed complete inactivation in pre-treatment and post-treatment in a volume of 200 µL; however, an incomplete inhibition was observed in post-treatment in the volume of 20 mL but still decreased by about 1.2-1.7 log CFU/mL when compared to the control and other individuals used after incubation for 48 h. The complete genome and G+C content of phages vB_AdhS_TS3, vB_AdhM_DL, and vB_AdhM_TS9 were 115,560, 61,429, and 115,503 bp, respectively, with G+C contents of 41.10%, 61.7%, and 35.34%, respectively. This study demonstrated using phages as an adjuvant with a sublethal concentration of antibiotics as an effective therapeutic strategy. IMPORTANCE Aeromonas dhakensis is widely distributed in the environment and can cause a variety of infections both in human and animals and is often misidentified with other members of the Aeromonas family, A. hydrophila, A. veronii, or A. caviae using the commercial test kits which has led to challenges in treating this pathogen. Hence, our study isolated phages against this bacterial strain and extensively characterized their efficacy with common antibiotics used to treat the pathogen.

[1]  Shikha Malik,et al.  Bacteriophage cocktail and phage antibiotic synergism as promising alternatives to conventional antibiotics for the control of multi-drug-resistant uropathogenic Escherichia coli. , 2021, Virus research.

[2]  Jeremy J. Barr,et al.  Phage Therapy in the Postantibiotic Era , 2019, Clinical Microbiology Reviews.

[3]  Patricia P. Chan,et al.  tRNAscan-SE: Searching for tRNA Genes in Genomic Sequences. , 2019, Methods in molecular biology.

[4]  G. El–Didamony,et al.  New Approach to Use Phage Therapy against Aeromonas hydrophilaInduced Motile Aeromonas Septicemia in Nile Tilapia , 2016 .

[5]  Michael Avidon,et al.  of Three Species , 2016 .

[6]  M. Figueras,et al.  Aeromonas aquatica sp. nov., Aeromonas finlandiensis sp. nov. and Aeromonas lacus sp. nov. isolated from Finnish waters associated with cyanobacterial blooms. , 2015, Systematic and applied microbiology.

[7]  P. Tsai,et al.  Clinical Implications of Species Identification in Monomicrobial Aeromonas Bacteremia , 2015, PloS one.

[8]  G. Richards Bacteriophage remediation of bacterial pathogens in aquaculture: a review of the technology , 2014, Bacteriophage.

[9]  Torsten Seemann,et al.  Prokka: rapid prokaryotic genome annotation , 2014, Bioinform..

[10]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[11]  Mai Huong Ly-Chatain,et al.  The factors affecting effectiveness of treatment in phages therapy , 2014, Front. Microbiol..

[12]  Sergey I. Nikolenko,et al.  SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-Cell Sequencing , 2012, J. Comput. Biol..

[13]  S. Abedon,et al.  Phage therapy pharmacology. , 2010, Current pharmaceutical biotechnology.

[14]  A. Martínez-Murcia,et al.  Clinical Relevance of the Recently Described Species Aeromonas aquariorum , 2009, Journal of Clinical Microbiology.

[15]  Paul Stothard,et al.  The CGView Server: a comparative genomics tool for circular genomes , 2008, Nucleic Acids Res..

[16]  J. Picazo,et al.  In Vitro Activities of Tigecycline against Erythromycin-Resistant Streptococcus pyogenes and Streptococcus agalactiae: Mechanisms of Macrolide and Tetracycline Resistance , 2004, Antimicrobial Agents and Chemotherapy.

[17]  V. Jansen,et al.  Pharmacokinetic Principles of Bacteriophage Therapy , 2003, Clinical pharmacokinetics.

[18]  森田 修,et al.  Aeromonas hydrophila による下腿壊死性筋膜炎の治療経験 , 2001 .

[19]  L. Ashdown,et al.  In vitro susceptibilities of tropical strains of Aeromonas species from Queensland, Australia, to 22 antimicrobial agents , 1993, Antimicrobial Agents and Chemotherapy.

[20]  Evon M. O. Abu-Taieh,et al.  Comparative Study , 2020, Definitions.